Central Council for Research in Ayurvedic Sciences (CCRAS), an autonomous body under the Ministry of AYUSH and ICMR's regional research centre in Belgaum in Karnataka are carrying out the trials.
"Clinical trials on dengue drug are in advanced stages. CCRAS and ICMR are conducting it in Belgaum to test the clinical safety and efficacy. The drug had earlier been standarised and after we got positive leads on it last year, we decided to go for the trials," Joint Secretary, AYUSH Ministry, A K Ganeriwala, said.
Director General of ICMR Soumya Swaminathan said, "our partnership in the trials would mean that the claims of efficacy of Ayurveda drugs would be validated scientifically."
"The advanced stages of the trials began few weeks ago at our research facility in Begaum," she said.
Asked if any similar trials could be done for chikungunya, she said, "it could be taken up".
Ganeriwala said the trials had begun almost a year ago and went through various stages.
A senior official at AYUSH Ministry said, "In ancient texts like 'Charak Sanhita', the concept of 'jwara (fever) and its cure has been mentioned, though dengue or chikungunya doesn't find a mention, as the nomenclature came up in last several decades.
Currently there is no drug for dengue in India.
At least 21 deaths due to dengue have been reported at various hospitals in Delhi, including nine at AIIMS, while over 3,000 people have been afflicted by the vector-borne disease in the national capital.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
